Switch Therapeutics
- Biotech or pharma, therapeutic R&D
Switch is developing conditionally activated siRNA (CASi) to treat CNS diseases with greater precision. Our triple stranded CASi molecules achieve excellent brain distribution and exhibit long duration of effect. CASi molecules can be designed to activate only in the targeted cell type. Our first programs target APOE (development candidate nominated) and MAPT with a Universal CASi that remains in an inactive state in the liver. Our first cell specific CASi molecules activate only in microglia. Our first microglial target is C1QA.
Switch raised a $52M Series A in 2023 co-led by Insight Partners and UCB Ventures. Participating investors included Lilly Ventures, Ono Ventures, Dolby Family Ventures, Upfront Ventures, Ono Ventures, and others.
Address
South San FranciscoCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}